دورية أكاديمية
أعرض في EDS

Antibiotic-Potentiating Effect of Some Bioactive Natural Products against Planktonic Cells, Biofilms, and Virulence Factors of Pseudomonas aeruginosa .

التفاصيل البيبلوغرافية
العنوان: Antibiotic-Potentiating Effect of Some Bioactive Natural Products against Planktonic Cells, Biofilms, and Virulence Factors of Pseudomonas aeruginosa .
المؤلفون: Chimi LY; Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon., Bisso BN; Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon., Njateng GSS; Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon., Dzoyem JP; Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon.
المصدر: BioMed research international [Biomed Res Int] 2023 Aug 23; Vol. 2023, pp. 9410609. Date of Electronic Publication: 2023 Aug 23 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Hindawi Pub. Co.
مواضيع طبية MeSH: Anti-Bacterial Agents*/pharmacology , Biological Products*/pharmacology, Humans ; Amikacin ; Pseudomonas aeruginosa ; Biofilms
مستخلص: Background: Pseudomonas aeruginosa is an opportunistic human pathogen that causes infections that are mediated by both virulence factor production and biofilm formation. In addition, many antibiotics are increasingly losing their efficacy due to the development of resistance. The screening of potentially bioactive natural compounds that have both antivirulence and antibiofilm activities to enhance antibiotic efficacy and reverse antibiotic resistance is a good strategy to overcome these issues. In this study, the antibacterial, antibiofilm, and antivirulence factor activities of some bioactive natural products in combination with conventional antibiotics were evaluated against clinical isolates of P. aeruginosa .
Methods: The broth microdilution method was used to determine the antibacterial and antibiofilm activities. The checkerboard method was used to evaluate the combination interactions. Spectrophotometric and agar plate techniques were used to assess the effect of the combination on the pyocyanin production and the motility in P. aeruginosa ATCC 27853 strain.
Results: Out of the eighteen combinations tested, ten exhibited synergistic effects against planktonic cells, seven against biofilm inhibition, and five against the eradication of mature biofilm of P. aeruginosa biofilm. The best synergistic effect was the association of amikacin and sinapic acid against planktonic cells (FICI = 0.08) with a 70-fold reduction in the MIC value of amikacin. The same combination showed significant synergistic inhibition of biofilm formation (FICI = 0.1) and biofilm eradication (FICI = 0.15) reducing the MBIC and MBEC of amikacin by 32-fold. Some selected synergistic combinations showed statistically significant differences ( p < 0.01 or p < 0.001) in the inhibition of virulence factors compared to the antimicrobials alone.
Conclusion: In summary, this study revealed sinapic acid as an antibiotic adjuvant and antivirulence compound to overcome P. aeruginosa infections. This finding indicates that the combinations of amikacin plus sinapic acid, ceftazidime plus thymol, and norfloxacin plus curcumin could be considered promising candidates for the development of combination therapies targeting virulence factors against P. aeruginosa infections.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2023 Larissa Yetendje Chimi et al.)
References: Postepy Hig Med Dosw (Online). 2017 Feb 14;71(0):78-91. (PMID: 28258668)
Braz J Microbiol. 2020 Sep;51(3):1079-1092. (PMID: 32394240)
ScientificWorldJournal. 2023 Mar 31;2023:6080489. (PMID: 37035538)
Evid Based Complement Alternat Med. 2021 Oct 27;2021:1567017. (PMID: 34745275)
Biomedicines. 2020 Oct 11;8(10):. (PMID: 33050619)
Phytomedicine. 2008 Aug;15(8):639-52. (PMID: 18599280)
Antibiotics (Basel). 2022 Jan 10;11(1):. (PMID: 35052956)
Int J Mol Sci. 2021 Mar 18;22(6):. (PMID: 33803907)
Evid Based Complement Alternat Med. 2022 Jul 21;2022:1936165. (PMID: 35911151)
Mol Biol Rep. 2021 Apr;48(4):3733-3745. (PMID: 33988797)
J Clin Pathol. 2020 May;73(5):261-266. (PMID: 32213553)
Antibiotics (Basel). 2020 Dec 23;10(1):. (PMID: 33374551)
Nucleic Acids Res. 2022 Jan 7;50(D1):D1324-D1333. (PMID: 34664659)
Front Microbiol. 2021 Nov 15;12:789765. (PMID: 34867928)
Clin Microbiol Rev. 2013 Apr;26(2):185-230. (PMID: 23554414)
Can J Infect Dis Med Microbiol. 2023 Jan 16;2023:7274309. (PMID: 36698730)
Toxins (Basel). 2016 Aug 09;8(8):. (PMID: 27517959)
PLoS One. 2017 Feb 24;12(2):e0172273. (PMID: 28235054)
BMC Complement Altern Med. 2014 May 05;14:147. (PMID: 24885143)
Can J Infect Dis Med Microbiol. 2021 Nov 08;2021:7029944. (PMID: 34790281)
Molecules. 2020 Oct 29;25(21):. (PMID: 33138250)
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192. (PMID: 30500353)
Braz J Microbiol. 2015 Mar 01;46(1):149-54. (PMID: 26221101)
Front Immunol. 2022 Jan 13;12:814709. (PMID: 35095914)
Front Cell Infect Microbiol. 2022 Jul 06;12:926758. (PMID: 35873152)
FEMS Microbiol Lett. 2017 Aug 15;364(15):. (PMID: 28605563)
APMIS. 2017 Apr;125(4):304-319. (PMID: 28407419)
Cell Metab. 2020 Jun 2;31(6):1091-1106.e6. (PMID: 32428444)
Curr Microbiol. 2018 Jul;75(7):787-793. (PMID: 29427006)
Front Microbiol. 2022 Aug 26;13:955286. (PMID: 36090087)
MethodsX. 2021 Oct 11;8:101543. (PMID: 34754811)
Int J Environ Res Public Health. 2018 Oct 22;15(10):. (PMID: 30360435)
Chem Biol Interact. 2019 Aug 1;308:294-303. (PMID: 31158333)
Nat Rev Drug Discov. 2021 Mar;20(3):200-216. (PMID: 33510482)
المشرفين على المادة: 0 (Anti-Bacterial Agents)
84319SGC3C (Amikacin)
68A28V6010 (sinapinic acid)
0 (Biological Products)
تواريخ الأحداث: Date Created: 20230904 Date Completed: 20230905 Latest Revision: 20230905
رمز التحديث: 20230905
مُعرف محوري في PubMed: PMC10470073
DOI: 10.1155/2023/9410609
PMID: 37663785
قاعدة البيانات: MEDLINE
الوصف
تدمد:2314-6141
DOI:10.1155/2023/9410609